CGM Integrated Sensor System Patent Landscape 2026
The CGM integrated sensor system space is highly concentrated, with Medtronic MiniMed holding a commanding lead over Abbott Diabetes Care and a fragmented tier of challengers. The field is in a growth stage on a multi-year basis, though annual filing volume has eased from its 2018 peak and recent years remain understated by publication lag.
Medtronic MiniMed dominates a highly concentrated field
Medtronic MiniMed Inc is the clear leader, ranking first with 47 patent records — more than double the output of second-placed Abbott Diabetes Care Inc at 18 patent records. The top five filers collectively account for 58% of the hundred largest filers’ combined total, signaling a pronounced concentration at the top of the competitive hierarchy.
A substantial tier gap separates the top two incumbents from the rest. Medtronic MiniMed and Abbott together account for the majority of the leading filers’ activity, while UXN (9 patent records), Willow Lab Inc and Dexcom Inc (7 each) form a distant mid-tier. Below that, Cambridge Enterprise Ltd and Insulet Corp (6 each) represent a third, more fragmented tier.
| # | Applicant | Patent records | Share |
|---|---|---|---|
| 1 | Medtronic MiniMed Inc | 47 | |
| 2 | Abbott Diabetes Care Inc | 18 | |
| 3 | UXN Ltd | 9 | |
| 4 | Willow Lab Inc | 7 | |
| 5 | Dexcom Inc | 7 | |
| 6 | Cambridge Enterprise Ltd | 6 | |
| 7 | Insulet Corp | 6 | |
| 8 | University of South Florida | 4 | |
| 9 | iSense Corp | 4 | |
| 10 | i-SENS Inc | 3 |
| # | Applicant | Patent records | Share |
|---|---|---|---|
| 11 | University of Padova | 3 | |
| 12 | Regents of the University of California | 3 | |
| 13 | i-SENS Inc | 2 | |
| 14 | Erwin S. Budiman | 2 | |
| 15 | William Kenneth Ward | 2 | |
| 16 | Gary A. Hayter | 2 | |
| 17 | Pacific Diabetes Technologies Inc | 2 | |
| 18 | Malgorzata E. Wilinska | 2 | |
| 19 | Marc B. Taub | 2 | |
| 20 | Ascensia Diabetes Care Holdings AG | 1 |
The leaders’ positions imply deep, layered portfolios spanning sensor diagnostics, healthcare informatics, and drug-delivery device integration — creating broad freedom-to-operate barriers for new entrants seeking to build end-to-end systems. Companies without equivalent depth in A61B and G16H coverage face meaningful design-around challenges.
The most recent 18–24 months of filing data are subject to publication lag and should be treated as undercounts; the true current filing rate is likely higher than raw 2024–2025 figures suggest. Longer-window growth, applicant concentration, and technology-route coverage are therefore more reliable signals than the latest-year bar alone.
Multi-year growth sustained despite a post-2018 moderation in annual volume
Two lenses reveal how the field has evolved: annual filing volume shows the trajectory of competitive urgency, while the IPC technology mix exposes where innovation effort is concentrated and where adjacent branches remain thin.
Annual filing trend
Filing activity surged to a peak in 2018 (28 patent records) before falling sharply in 2019–2020, then recovering steadily through 2022–2025. The recent three-year window sits 167% above the prior three-year window, confirming genuine multi-year expansion even as annual volume has not returned to the 2018 spike. Data for 2025–2026 are undercounted due to publication lag and should not be read as a slowdown.
↗ Hover for values · click a bar to ask EurekaTechnology composition
A61B (Diagnosis and surgery) dominates with 134 patent records, followed by G16H (Healthcare informatics) at 43 and G01N (Material analysis and testing) at 40 — reflecting the sensor-plus-data-management architecture at the core of CGM systems. AI-adjacent branches (G06N at 16, G06F at 6) and antenna technology (H01Q at 4) are present but sparse relative to the diagnostic core, pointing to areas of lower competitive density.
↗ Hover for values · click a bar to ask EurekaHighly cited patent families surfaced by the query
Citation-heavy patent families returned by the query. Use this section as citation context, not as a curated list of the most topic-specific patents.
Implantable continuous glucose monitor device
A continuous glucose monitor (CGM) sensor includes a glucose oxidation electrode and a counter electrode, and does not include a glucose-specific enzyme. The glucose oxidation electrode includes a nanoporous layer comprising metal nanoparticles. The CGM sensor generates an electrical signal indicative glucose oxidation in a liquid containing glucose, which… (excerpt from the patent abstract)
| # | Patent | Citations |
|---|---|---|
| 1 | Continuous glucose monitoring-directed adjustments… | 240 |
| 2 | Orthogonally Redundant Sensor Systems and Methods | 230 |
| 3 | Methods for reducing false hypoglycemia alarm occu… | 214 |
| 4 | Monitoring method and/or apparatus | 85 |
| 5 | Methods for reducing false hypoglycemia alarm occu… | 83 |
| 6 | Analyte monitoring system and methods of use | 75 |
| 7 | Methods, systems, and devices for calibration and … | 61 |
| 8 | Continuous glucose monitoring based on remote sens… | 52 |
Ranked by total forward citations. Citation counts favour older and broadly cited patent families, and broad or adjacent patents may appear when they match the search scope. Treat this section as citation context, not as a curated list of the most topic-specific patents. Some patent titles may be shown in their original, non-English language where an accurate translation could not be guaranteed.
What the competitive structure means for R&D investment decisions
The combination of high concentration, a growth-stage lifecycle, limited cross-sector collaboration, and a strong US jurisdictional anchor shapes where new R&D investment is likely to find the most and least resistance.
Growth stage — expanding on a multi-year basis, past the 2018 annual peak
The field is classified as Growth: the recent three-year filing window is 167% above the prior three-year window, confirming continued expansion in cumulative output. However, annual volume peaked in 2018 and has not returned to that level, indicating the market has passed an early burst phase and is now on a steadier growth trajectory. Entrants can still establish meaningful positions, but the window of maximum openness has likely narrowed.
Growth stageSteep two-player lead with a fragmented challenger tier
Medtronic MiniMed (47 patent records) and Abbott Diabetes Care (18) together define the top tier, with the top five filers holding 58% of the hundred largest filers’ combined total. The mid-tier — UXN, Willow Lab, Dexcom, Cambridge Enterprise, Insulet — is spread across 6–9 patent records each, suggesting no single challenger has yet built sufficient portfolio depth to threaten the leaders on breadth. Focused vertical strategies in underserved branches may offer a more viable entry path than head-on competition.
High concentrationLimited cross-institutional co-filing; Abbott–Cambridge and Dexcom–Padova are the active pairs
Co-applicant activity is sparse. Abbott Diabetes Care Inc and Cambridge Enterprise Ltd share the most active collaboration with 4 joint filings, suggesting a corporate–academic channel focused on algorithmic or sensing research. Dexcom Inc and the University of Padova have 1 joint filing. The absence of broader consortium activity leaves open the possibility of forming new academic or cross-industry partnerships in underserved technical branches without immediately confronting entrenched co-development networks.
Sparse ecosystemUS-centric filing with selective PCT and European validation
The United States accounts for 71 patent records at the jurisdiction level — the dominant single office by a wide margin. WIPO PCT (15) and EPO (14) filings follow, with Canada (9) and India (7) representing secondary markets. China holds only 1 patent record at this level, which is notable given its market size and manufacturing base. Competitors seeking global exclusivity should evaluate whether their PCT filings are being adequately nationalized into key growth markets.
US-dominantGo beyond the landscape: Eureka’s TRIZ Solution agent breaks down an R&D problem and returns patented concept solutions, each with a technical approach and cited patent & literature evidence.
| Applicant | Collaborator | Co-filings |
|---|---|---|
| Abbott Diabetes Care Inc | Cambridge Enterprise Ltd | 4 |
| Dexcom Inc | University of Padova | 1 |
Co-filing pairs, ranked by the number of jointly-filed patent families.
Medtronic MiniMed anchors the field; Abbott integrates device delivery with data
The two leading filers differ in their technical emphasis: Medtronic MiniMed focuses heavily on diagnostic sensing and informatics infrastructure, while Abbott Diabetes Care pairs sensor diagnostics with drug-delivery device integration. Both are classified as new entrants in the momentum data, reflecting their activity in the recent filing window.
Medtronic MiniMed Inc
Medtronic MiniMed leads the corpus with 47 patent records, concentrated across A61B 5 (diagnostic sensing, 45 records), G16H 40 (healthcare informatics, 17 records), and G01N 27 (electrochemical analysis, 16 records). This three-axis coverage — sensor hardware, data management, and analyte chemistry — represents one of the broadest integrated portfolios in the field. Momentum data shows 12 recent-period patent records, flagged as a new entrant trend in the tracking window.
patent records: 47Abbott Diabetes Care Inc
Abbott Diabetes Care Inc holds 18 patent records and differentiates through its pairing of A61B 5 sensor coverage (18 records) with A61M 5 drug-delivery device claims (12 records) and G16H 20 clinical decision-support informatics (9 records). This combination signals a strategy oriented toward closed-loop or semi-closed-loop systems bridging sensing and therapeutic response. With 4 recent-period records and a new entrant momentum flag, Abbott is an active filer despite its smaller total footprint relative to Medtronic MiniMed. Its collaboration with Cambridge Enterprise Ltd (4 joint filings) extends its research reach into academic sensing and algorithm development.
patent records: 18| Applicant | Recent (3 yrs) | Trend |
|---|---|---|
| Medtronic MiniMed Inc | 12 | ▲ new entrant |
| Abbott Diabetes Care Inc | 4 | ▲ new entrant |
| Dexcom Inc | 4 | ▲ new entrant |
| Insulet Corp | 6 | ▲ new entrant |
AI models and antenna design are under-served relative to the diagnostic core
Several IPC branches appear in the corpus at low share, meaning competitive density is substantially lower than in A61B or G16H. These are observations of relative sparsity; each should be evaluated against technical feasibility and a realistic path to commercialization before being treated as an investment target.
G06N · Computing based on AI models
With 16 patent records and a 5% share of IPC branch coverage, AI-model computing is the largest of the under-served adjacent branches in this corpus. CGM systems generate continuous time-series glucose data that are well-suited to predictive modeling, anomaly detection, and personalized dosing algorithms — all areas where AI/ML claims would logically extend existing sensor IP. The dominant players (Medtronic MiniMed, Dexcom) have informatics coverage in G16H but limited explicit G06N filings, suggesting a potential gap between commercial practice and formal patent protection that a focused AI-in-CGM strategy could address.
Search this in Eureka →H01Q · Antennas
H01Q holds only 4 patent records and a 1% share, making it the sparsest named branch in the corpus. As CGM systems increasingly rely on wireless data transmission to smartphones, cloud platforms, and closed-loop insulin pumps, antenna miniaturization and RF performance within wearable form factors become technically critical. The near-absence of antenna-specific filings by the dominant CGM players suggests this hardware layer may be addressed through component sourcing rather than proprietary IP — creating a potential entry point for antenna specialists or wearable-electronics firms seeking to supply or license into the CGM ecosystem.
Search this in Eureka →How leading filers differ across technology routes
Route coverage across the main technology branches in the current evidence set.
| Player | A61B 5 · Diagnosis & surgery | G16H 40 · Healthcare informatics | A61M 5 · Devices for body fluids | G16H 20 · Healthcare informatics | G16H 50 · Healthcare informatics |
|---|---|---|---|---|---|
| Medtronic MiniMed Inc | Strong · 45 | Moderate · 17 | Emerging · 7 | Moderate · 15 | Moderate · 16 |
| Abbott Diabetes Care Inc | Strong · 18 | Moderate · 9 | Strong · 12 | Moderate · 9 | Emerging · 3 |
| Dexcom Inc | Strong · 9 | Absent | Absent | Moderate · 4 | Moderate · 3 |
| Insulet Corp | Strong · 6 | Absent | Strong · 6 | Absent | Absent |
| Cambridge Enterprise Ltd | Strong · 4 | Strong · 4 | Absent | Strong · 4 | Absent |
Frequently asked questions
The corpus covers 92 patent families. This is the base count for the landscape; applicant rankings are reported in patent records, which can differ from the family count because a single family may generate records across multiple jurisdictions.
Medtronic MiniMed Inc leads with 47 patent records, more than double the 18 patent records held by second-ranked Abbott Diabetes Care Inc. The top five filers together account for 58% of the hundred largest filers’ combined total, confirming a highly concentrated competitive structure.
Yes, on a multi-year basis. The recent three-year filing window is 167% above the prior three-year window, placing the field in a Growth lifecycle stage. However, annual volume peaked in 2018 and has not returned to that level. Data for 2024–2025 are further undercounted due to publication lag and should not be interpreted as a slowdown.
The United States is the dominant filing office, accounting for 71 patent records at the jurisdiction level. WIPO PCT (15) and the EPO (14) are the next most important channels, followed by Canada (9) and India (7). China holds only 1 patent record at this level, which is notably low relative to its diabetes-patient population and manufacturing base.
G06N (Computing based on AI models) has 16 patent records and a 5% IPC share — the largest under-served adjacent branch. H01Q (Antennas) has only 4 patent records and a 1% share. Both are technically relevant to modern CGM architectures but have substantially lower competitive density than A61B (134 patent records) and G16H (43 patent records).
Collaboration is sparse. The most active co-filing pair is Abbott Diabetes Care Inc and Cambridge Enterprise Ltd with 4 joint patent records, suggesting a corporate–academic channel. Dexcom Inc and the University of Padova share 1 joint filing. No broader consortium activity is evident in the current evidence, leaving the collaborative ecosystem relatively open.
Ready to map your own CGM sensor patent landscape?
Join 18,000+ innovators using PatSnap Eureka to map any technology landscape: search 2B+ patents and papers, surface key assignees, and generate a report like this in minutes.
Disclaimer. This page is generated from PatSnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. PatSnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.